WOLFGANG WINKELMAYER to Erythropoietin
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Erythropoietin.
Connection Strength
4.116
-
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
Score: 0.450
-
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.
Score: 0.443
-
Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later. Am J Kidney Dis. 2013 Dec; 62(6):1217-20.
Score: 0.408
-
What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. Circulation. 2011 Dec 20; 124(25):2805-8.
Score: 0.357
-
The effect of altitude change on anemia treatment response in hemodialysis patients. Am J Epidemiol. 2011 Apr 01; 173(7):768-77.
Score: 0.337
-
Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. J Am Soc Nephrol. 2011 Jan; 22(1):1-2.
Score: 0.333
-
Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis. Semin Dial. 2010 Sep-Oct; 23(5):486-91.
Score: 0.326
-
The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008 Jul; 19(7):1389-95.
Score: 0.276
-
Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023 09 29; 38(10):2358-2367.
Score: 0.202
-
Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Am J Nephrol. 2022; 53(10):701-710.
Score: 0.190
-
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
Score: 0.186
-
Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014 May; 174(5):699-707.
Score: 0.105
-
Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009 Oct; 18(10):932-40.
Score: 0.076
-
Altitude and all-cause mortality in incident dialysis patients. JAMA. 2009 Feb 04; 301(5):508-12.
Score: 0.073
-
Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients. Arch Intern Med. 2007 Apr 23; 167(8):840-6.
Score: 0.065
-
Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr Nephrol. 2007 Aug; 22(8):1189-93.
Score: 0.064
-
Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004 Oct; 66(4):1712; author reply 1712-3.
Score: 0.054
-
Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol. 2004 May; 15(5):1347-52.
Score: 0.053
-
The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003 Jul; 64(1):295-304.
Score: 0.050
-
Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant. 2021 11 09; 36(11):2039-2048.
Score: 0.044
-
The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med. 2013 Jun; 126(6):541.e1-541.e14.
Score: 0.024